Business Context and Reporting Period
This Form 6-K was filed by NLS Pharmaceutics Ltd., despite the request metadata identifying Newcelx Ltd. The report covers December 2021 and was signed on December 15, 2021. It reports an amendment dated December 14, 2021 to the company’s Standby Equity Distribution Agreement with YA II PN, Ltd. (YA).
Key Financial Metrics and Capital Structure
The filing does not provide revenue, profit, cash flow, margins, debt, cash, or liquidity balances.
- The amended equity facility permits the company to issue advance notices for amounts up to the lesser of 100% of the average daily trading value of its common shares during the preceding five consecutive trading days or $4.0 million.
- The amendment permits the company to specify a minimum acceptable price instead of using the facility’s defined advance price.
- The minimum acceptable price may not exceed 85% of the volume-weighted average price on the last completed trading day before delivery of an advance notice.
Material Changes Versus the Prior Comparable Period
The principal reported change is an amendment to the SEDA executed on September 27, 2021. The filing does not report completed sales, proceeds received, shares issued, or changes in financial results.
Guidance, Outlook, Risks, and Unusual Items
- The amendment provides additional flexibility in the timing, size, and pricing of potential equity sales to YA.
- Any use of the facility could result in issuance of common shares at a discount to market price, creating potential dilution for existing shareholders.
- The filing does not state whether the company had delivered an advance notice or drawn under the amended facility as of the filing date.
- The complete terms are contained in Exhibit 99.1, Amendment No. 1 to the Standby Equity Distribution Agreement.
Investor Verification Checklist
- Confirm the registrant’s identity, because the filing names NLS Pharmaceutics Ltd., not Newcelx Ltd.
- Review Exhibit 99.1 for the full mechanics, conditions, and termination provisions of the amended SEDA.
- Verify whether any advance notices, share issuances, or proceeds occurred after the amendment.
- Assess potential dilution and the applicable pricing discount if the facility is used.
- Check subsequent filings for the company’s cash position, financing needs, and use of proceeds.